Biocity Biopharmaceutics Co., Ltd.
Biocity Biopharmaceutics Co., Ltd.
Explore linked clinical trials.5 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | Locally Advanced or Metastatic Solid Tumors | Recruiting | Phase 1 / Phase 2 | 2026-05-28 | NCT07469774 | |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of BC2027 in Patients With Advanced Solid Malignancies | Advanced Solid Malignancies | Recruiting | Phase 1 | 2026-01-26 | NCT07368478 | |
| dApagliflozin SC0062 and Prevention of Renal Injury; a Randomized Evaluation | Diabetes Complications, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Nutritional and Metabolic Diseases, Urogenital Diseases, autoimmune disease, diabetes mellitus, diabetic kidney disease, endocrine system disorder, glucose metabolism disease, immune system disorder, kidney disorder, metabolic disease, type 1 diabetes mellitus, urinary system disorder | Not yet recruiting | Phase 2 | 2025-10-07 | NCT06072326 | |
| A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, IgA glomerulonephritis, Male Urogenital Diseases, Urogenital Diseases, autoimmune disease, glomerulonephritis, immune system disorder, kidney disorder, nephritis, urinary system disorder | Recruiting | Phase 3 | 2025-02-17 | NCT06819826 | |
| A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or Metastatic Cancer | Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, neoplasm | Recruiting | Phase 1 | 2024-08-12 | NCT06548672 |